Drug Trial Radar · NCT05743179
The Effect of Zoledronate on the Prevention of Pneumonia in Hip Fracture Patients
Last checked: Nov 19, 2026Latest source record: Feb 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
2,692
Planned (sponsor's estimate)
Start
Dec 5, 2022
Primary completion
May 2025
Study completion Jun 2025
Sponsor
- Lead sponsor
- The University of Hong KongAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Queen Mary Hospital, Hong Kong; Caritas Medical Centre, Hong Kong; Prince of Wales Hospital, Shatin, Hong Kong; United Christian Hospital
- First posted
- Feb 24, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Nitrogen-containing bisphosphonates (N-BPs; such as alendronate and zoledronate) are commonly used in the treatment of osteoporosis and fracture prevention, in which zoledronate has a proven better efficacy than alendronate. In 2018, our real-world propensity score matched study showed that the use of N-BPs was significantly associated with reduced risk of myocardial infarction and stroke in hip fracture patients. In addition to cardiovascular diseases, both preclinical study and sensitivity analysis also suggest evidence for N-BPs in pneumonia prevention. Moreover, a pragmatic clinical trial is developed to evaluate effect of the tested intervention in real-life routine clinical practice since traditional explanatory radomised controlled trial (RCT) may have poor generalizability due to highly selected patients and controlled environments. This study aims to evaluate if zoledronate reduces risk of pneumonia in hip fracture patients using pragmatic clinical trial approach. This is an open-label, multi-centre, pragmatic, randomised controlled trial. Patients will be recruited from 4 hospitals, namely Caritas Medical Centre, Prince of Wales Hospital, Queen Mary Hospital, and United Christian Hospital. Age, sex, body mass index, eGFR, history of fracture, chronic respiratory diseases, and other medical history, will be measured and recorded at recruitment.
Conditions
- Hip Fractures
- Pneumonia
Interventions
ZoledronateDrug
Aclasta Solution for Infusion 5mg/100ml (zoledronic acid)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pneumonia hospitalizationsTime frame: 12 months
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Queen Mary Hospital
Hong Kong, Hong Kong · Recruiting
United Christian Hospital
Kwun Tong, Hong Kong · Recruiting
Caritas Medical Centre
Sham Shui Po, Hong Kong · Recruiting
Prince of Wales Hospital
Shatin, Hong Kong · Not yet recruiting
Tai Po Hospital
Tai Po, Hong Kong · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.